Company intelligence / Profile preview

NovoGlia

Aliso Viejo, California, United Stateslegacy.www.sbir.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

NovoGlia is developing a gene-corrected, stem cell-derived microglial therapy for ALSP. The company has received funding to conduct preclinical studies evaluating the efficacy and safety of this approach. No clinical results have been reported yet; the program remains in preclinical development.[3]

Therapeutic areas: Neurology
Modalities: Cell therapyInduced pluripotent stem cell (iPSC)-derived microglia[2][5]
Industry: Biotech

Beyond the preview

Go deeper on NovoGlia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovoGlia.

Explore the full profile